New York, May 22, 2026, 12:05 (EDT)
Caribou Biosciences shares traded up Friday, sitting close to $2. Investors mostly shrugged off a slow news day, focusing instead on cancer-drug updates expected next month.
The stock was at $2.01, about 1% higher than Thursday’s $1.99 close. It swung from $1.972 to $2.040. Market value stood near $198 million, according to Investing.com data.
Timing is in focus. Trading is set ahead of a three-day U.S. market weekend, as Nasdaq’s 2026 calendar shows U.S. equity and options markets will be closed for Memorial Day on May 25.
Caribou’s next key moment isn’t coming on Friday’s trading. It’s all about data. The company announced on May 12 that two abstracts made it into oral sessions at the European Hematology Association meeting in Stockholm in June. The talks will focus on vispa-cel and CB-011, Caribou’s main off-the-shelf cancer cell therapy programs.
CAR-T is a cancer treatment that reprograms T-cells to find and kill cancer. Caribou is focused on allogeneic CAR-T, using donor cells made in advance, instead of custom therapies from a patient’s own cells.
Caribou CEO Rachel Haurwitz said earlier this month the company has “aligned with the FDA on the pivotal ANTLER-3 trial design” for vispa-cel. The trial is set to enroll about 250 large B-cell lymphoma patients who need second-line treatment and aren’t on transplant or autologous CAR-T. Progression-free survival is the primary endpoint, measuring how long it takes for the disease to worsen or for patients to die. SEC
Small changes in CRBU tend to stand out. Caribou is looking to shift from early-stage results into a bigger, late-stage study, an expensive move for a firm that is not close to getting product revenue.
Caribou reported $118.6 million in cash, cash equivalents and marketable securities as of March 31, down from $142.8 million at the end of last year. The company expects that cash to support its current plan into the second half of 2027. Caribou also said it is looking at ways to fully fund the vispa-cel pivotal trial.
Caribou sold roughly 1.08 million shares in the first quarter under its at-the-market program, pulling in $2.3 million gross at an average price of $2.11 per share, according to a filing. The at-the-market setup allows the company to sell shares over time, which raises cash but can dilute current holders. Caribou still had $93.4 million left to tap from the plan as of March 31.
The field is crowded. The FDA lists Bristol Myers Squibb’s Breyanzi as a CD19-directed autologous T-cell therapy for adult large B-cell lymphoma in a number of scenarios. Yescarta’s approved uses include adult large B-cell lymphoma that does not respond to first-line chemoimmunotherapy or comes back within 12 months.
Caribou says its advantage is speed and access, since its off-the-shelf product could sidestep some manufacturing lags of patient-specific options. But Caribou still needs to show safety, durability and efficacy in bigger trials.
Risks are clear. If June data fail to confirm durability, or if regulators or doctors ask for more proof, or Caribou raises cash for late-stage trials by selling shares cheaply, the stock could face fresh pressure. Caribou has said early or interim clinical data might not match final outcomes, and it’s still relying on financing, partnerships or new capital to keep funding work.
